NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-08-31
Reading ZTS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Sustain revenue growth near guidance level: FY26 rev guide $9.12B-$9.32B vs $9.82B target.
Zoetis leads in pet and livestock medicine with steady revenue growth. International sales rose 17%, showing strong global demand. The company targets about $9.82 billion revenue and $6.92 EPS in 2026. It maintains a cheap valuation with a PE of 11.8 versus peers at 25.
Revenue growth is slowing with only 3% recent increase. Cost control is weak as operating income fell from $798M to $758M. Guidance was cut and analysts expect challenges ahead. Competitive pressures and delayed product stabilization risk future earnings.
The stock trades about 20% below our fair value near $96, reflecting cautious views. Analysts expect roughly 4.5% revenue growth, which aligns with our moderate outlook. The market prices in some near-term weakness but not a severe downturn.
Breaks if: operating income declines below $700 million quarterly
Breaks if: EPS falls below $6.5
international revenue growth falls below 10% YoY
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on innovation and international growth. The current thesis state is intact, supported by strong recent financial performance and management's commitment to revenue growth.
The valuation is considered cheap compared to peers, with a low expectations gap. The market seems to reflect a cautious view on execution quality, but not overly pessimistic about the company's potential.
Fundamentals are likely to remain stable, driven by ongoing product approvals and international revenue growth. However, there is an elevated risk due to the potential for guidance cuts and the overall economic backdrop.
The thesis hinges on several factors, including the performance of key sector peers and the company's ability to maintain its growth trajectory. Monitoring the jobs report and any guidance changes will be crucial.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on ZTS. However, revenue growth guidance for 2026 has been cut, which poses a threat. New product approvals may help drive revenue growth, but concerns about the growth story remain.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: annual revenue falls below $9.4 billion
Overall, Zoetis shows promise for the next 1 to 3 years, supported by its strategic priorities and market position. Not investment advice.
